目的 探究舒肝解郁膠囊聯(lián)合阿戈美拉汀治療腦梗死后抑郁的臨床療效。方法 選取2015年1月-2016年12月哈勵(lì)遜國(guó)際和平醫(yī)院收治的腦梗死后抑郁患者68例，隨機(jī)分為對(duì)照組和治療組，每組各34例。對(duì)照組患者口服阿戈美拉汀片，25~50 mg/d。治療組患者在對(duì)照組的基礎(chǔ)上口服舒肝解郁膠囊，2粒/次，2次/d。兩組患者均連續(xù)治療8周。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者漢密爾頓抑郁量表（HAMD）和焦慮量表（HAMA）評(píng)分以及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為79.41%、91.18%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者HAMD和HAMA評(píng)分均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者HAMD和HAMA評(píng)分低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組患者不良反應(yīng)的發(fā)生率為20.58%，顯著低于對(duì)照組患者的29.41%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 舒肝解郁膠囊聯(lián)合阿戈美拉汀能夠有效的消除腦梗死患者的負(fù)面情緒，提高患者的生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Shugan Jieyu Capsules combined with aggameline in treatment of depression after cerebral infarction. Methods Patients (68 cases) with depression after cerebral infarction in Harrison International Peace Hospital from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were po administered with Agomelatine Tablets, 25-50 mg/d. Patients in the treatment group were po administered with Shugan Jieyu Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the HAMD scores, HAMA scores and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.41% and 91.18%, respectively, and there were differences between two groups (P<0.05). After treatment, the HAMD and HAMA scores in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the HAMD and HAMA scores in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). During the treatment, the incidence of adverse reactions in the treatment was 20.58%, which was significantly lower than 29.41% in the control group, with significant difference between two groups (P<0.05). Conclusion Shugan Jieyu Capsules combined with aggameline can effectively eliminate the patients' negative emotions and improve the quality of life in treatment of depression after cerebral infarction, which has a certain clinical application value.